Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:6409485rdf:typepubmed:Citationlld:pubmed
pubmed-article:6409485lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C0023516lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C0010583lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C0032950lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C0031437lld:lifeskim
pubmed-article:6409485lifeskim:mentionsumls-concept:C1280500lld:lifeskim
pubmed-article:6409485pubmed:issue1lld:pubmed
pubmed-article:6409485pubmed:dateCreated1983-9-20lld:pubmed
pubmed-article:6409485pubmed:abstractTextThe cell surface phenotype of human peripheral blood mononuclear cells has been characterized before and after intravenous injection of cyclophosphamide or prednisolone. Low doses of cyclophosphamide (100-600 mg/m2) temporarily decrease levels of circulating B lymphocytes. Slightly higher doses of cyclophosphamide (200-600 mg/m2) produce transient depression of T8-, M1-, and Ia-positive cells. After doses of 200-400 mg cyclophosphamide/m2, T4-positive cells are spared, resulting in a transient elevation of the T4/T8 ratio. With higher doses of cyclophosphamide (greater than or equal to 600 mg/m2), all T cells are affected and the T4/T8 ratio declines to pretreatment levels. By contrast, intravenous injection of prednisolone at 40 mg/m2 reduces the T4/T8 ratio. Levels of both T4 and T8 cells decline, but T4 cells are affected more markedly than T8 cells.lld:pubmed
pubmed-article:6409485pubmed:languageenglld:pubmed
pubmed-article:6409485pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:citationSubsetIMlld:pubmed
pubmed-article:6409485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:6409485pubmed:statusMEDLINElld:pubmed
pubmed-article:6409485pubmed:monthJullld:pubmed
pubmed-article:6409485pubmed:issn0090-1229lld:pubmed
pubmed-article:6409485pubmed:authorpubmed-author:SchlossmanS...lld:pubmed
pubmed-article:6409485pubmed:authorpubmed-author:ReinherzE LELlld:pubmed
pubmed-article:6409485pubmed:authorpubmed-author:MaverCClld:pubmed
pubmed-article:6409485pubmed:authorpubmed-author:BartT HTHlld:pubmed
pubmed-article:6409485pubmed:authorpubmed-author:LavinPPlld:pubmed
pubmed-article:6409485pubmed:issnTypePrintlld:pubmed
pubmed-article:6409485pubmed:volume28lld:pubmed
pubmed-article:6409485pubmed:ownerNLMlld:pubmed
pubmed-article:6409485pubmed:authorsCompleteYlld:pubmed
pubmed-article:6409485pubmed:pagination101-14lld:pubmed
pubmed-article:6409485pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:meshHeadingpubmed-meshheading:6409485-...lld:pubmed
pubmed-article:6409485pubmed:year1983lld:pubmed
pubmed-article:6409485pubmed:articleTitleContrasting effects of cyclophosphamide and prednisolone on the phenotype of human peripheral blood leukocytes.lld:pubmed
pubmed-article:6409485pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:6409485pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6409485lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6409485lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6409485lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:6409485lld:pubmed